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A B S T R A C T
Background
Glucocorticoids play a major role in the treatment of acute lymphoblastic leukaemia (ALL). However, supraphysiological doses may
cause suppression of the hypothalamic-pituitary-adrenal (HPA) axis. HPA axis suppression resulting in reduced cortisol response may
cause an impaired stress response and an inadequate host defence against infections, which remains a cause of morbidity and death.
The exact occurrence and duration of HPA axis suppression after glucocorticoid therapy for childhood ALL are unclear.
Objectives
To examine the occurrence and duration of HPA axis suppression after (each cycle of ) glucocorticoid therapy for childhood ALL.
Search methods
We searched the Cochrane Central Register of Controlled Trials (in The Cochrane Library, issue 3, 2010), MEDLINE/PubMed (from
1945 to July 2010) and EMBASE/Ovid (from 1980 to July 2010). In addition, we searched reference lists of relevant articles, conference
proceedings and ongoing trial databases.
Selection criteria
All study designs, except case reports and patient series with fewer than 10 patients, examining the effect of glucocorticoid therapy for
childhood ALL on the HPA axis function.
Data collection and analysis
Two review authors independently performed the study selection. One review author performed the data extraction and ’Risk of bias’
assessment, which was checked by another review author.
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Main results
We identified seven studies (total number of participants = 189), including one randomised controlled trial (RCT), which assessed the
adrenal function. None of the studies assessed the HPA axis at the level of the hypothalamus, pituitary, or both. Due to substantial
differences between studies, results could not be pooled. All studies had some methodological limitations. The included studies
demonstrated that adrenal insufficiency occurs in nearly all patients in the first days after cessation of glucocorticoid treatment for
childhood ALL. Themajority of patients recovered within a few weeks, but a small amount of patients had ongoing adrenal insufficiency
lasting up to 34 weeks. In the RCT, the occurrence and duration of adrenal insufficiency did not differ between the prednisolone and
dexamethasone arms. In one study included in the review it appeared that treatment with fluconazole prolonged the duration of adrenal
insufficiency.
Authors’ conclusions
Based on the available evidence, we conclude that adrenal insufficiency commonly occurs in the first days after cessation of glucocorticoid
therapy for childhood ALL, but the exact duration is unclear. Since no data on the level of the hypothalamus and the pituitary were
available we cannot make any conclusions regarding those outcomes. Clinicians should consider prescribing glucocorticoid replacement
therapy during periods of serious stress in the first weeks after cessation of glucocorticoid therapy for childhood ALL, to reduce the
risk of life-threatening complications. However, more high-quality research is needed for evidence-based guidelines for glucocorticoid
replacement therapy.
Special attention should be paid to patients receiving fluconazole therapy, and perhaps similar antifungal drugs, as this may prolong
the duration of adrenal insufficiency.
P L A I N L A N G U A G E S U M M A R Y
Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lym-
phoblastic leukaemia
Acute lymphoblastic leukaemia (ALL) is the most frequent type of cancer in children. Glucocorticoids, like prednisone and dexametha-
sone, play a major role in the treatment of ALL. However, high-dose glucocorticoids may cause HPA axis suppression. Suppression of
the HPA axis, resulting in inadequate cortisol production, may cause an impaired response to stressors (e.g. trauma, surgery or inflam-
mation) and an inadequate host defence against infections and remains a cause of morbidity and death in childhood. The occurrence
and duration of HPA axis suppression after glucocorticoid therapy for childhood ALL are unclear.
This systematic review included six cohort studies and one randomised study, which assessed the adrenal function. None of the studies
assessed the HPA axis at the level of the hypothalamus, pituitary, or both. All studies had some methodological limitations and results
could not be pooled because of the heterogeneity. Adrenal insufficiency occurred in nearly all of the patients in the first days after
cessation of glucocorticoid therapy. The majority of patients recovered within a few weeks, but a small number of patients had ongoing
adrenal insufficiency lasting up to 34 weeks. More high-quality research is needed to assess the exact occurrence and duration of HPA
axis suppression in order to formulate adequate guidelines for glucocorticoid replacement therapy.
B A C K G R O U N D
Of all malignancies in children, acute lymphoblastic leukaemia
(ALL) is themost frequent type. Annually, approximately 120 chil-
dren with ALL are newly diagnosed in the Netherlands (DCOG
2008). Since treatment and survival rates of childhood ALL have
substantially improved over time, morbidity and mortality due
to treatment-related side effects become increasingly important.
Unfortunately, up to 5% of children die because of the toxic side
effects of treatment, and this percentage becomes even greater in
higher-risk subgroups. The main cause of this treatment-related
mortality is infection associated with cytotoxic and immunosup-
pressive drugs (Christensen 2005; Pruckner 2009; Rubnitz 2004;
Wheeler 1996). Glucocorticoid therapy is an important contribut-
ing factor to the occurrence and severity of infection (Te Poele
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2007). In addition, several studies report an increase in sepsis and
lethal infections in children with ALL since prednisone has been
substituted for the more potent glucocorticoid dexamethasone
(Hurwitz 2000; Igarashi 2005; Te Poele 2007).
Glucocorticoids play a major role in the treatment of ALL. They
induce apoptosis of the lymphoblastic cells (Planey 2000). Chil-
dren with ALL receive cyclic courses of high-dose glucocorticoids,
like prednisone (or prednisolone) and dexamethasone. However,
supraphysiological doses of glucocorticoidsmay suppress hypotha-
lamic secretion of corticotrophin-releasing hormone (CRH) and
of adrenocorticotropic hormone (ACTH) by the pituitary gland,
resulting in secondary adrenal cortex atrophy with delayed re-
covery of hypothalamic-pituitary-adrenal (HPA) axis function. In
states of profound or prolonged ACTH deficiency, the adrenal
glands may temporarily be unable to generate sufficient cortisol
(Henzen 2000; Krasner 1999). Supraphysiological glucocorticoid
therapy is the most common cause of secondary adrenal insuffi-
ciency (Shulman 2007). The HPA axis plays a major role in the
stress response and host defence against infection. Stressors such
as trauma, surgery or inflammation stimulate the HPA axis, lead-
ing to an increase in cortisol production. In turn, increased cor-
tisol levels cause anti-inflammatory effects and inhibition of pro-
inflammatory cytokines (Hettmannsperger 1992; Nyhlén 2000;
Waage 1988). Suppression of the HPA axis resulting in reduced
adrenal cortisol production represents an impaired stress response
and an inadequate host defence against infections and remains a
cause of morbidity and death in childhood (Shulman 2007).
There are different well-established tests of HPA axis function.
Morning serum cortisol value reflects basal adrenal function but
gives no indication of the capacity to respond to stress (Agwu
1999; Schlaghecke 1992). Stimulation tests are used to assess the
HPA axis response to stress. The insulin-tolerance-test is consid-
ered the most reliable test to evaluate the HPA axis function at the
level of the pituitary and the adrenal gland, but is associated with
potentially dangerous side effects (Shah 1992). The CRH stim-
ulation test is only indicated in patients with a central disorder
of the HPA axis (Maghnie 2005; Van Tijn 2008). The glucagon
test has also been proven to be a safe and reliable method for
testing HPA axis function at the level of the pituitary and the
adrenal gland, but may also induce mild inadvertent side effects
(Böttner 2005; Rao 1987; Vanderschueren-Lodeweyckx 1974). A
well-established alternative to test the HPA axis at the level of the
adrenal gland without undesirable side effects is the low-dose (1
µg) ACTH stimulation test. This test is able to detect more subtle
degrees of adrenal atrophy caused by central adrenal insufficiency
compared to the “normal” ACTH stimulation test (250 µg). The
results of the low-dose ACTH test closely correlate with those of
the insulin-tolerance-test (Abdu 1999; Dickstein 1997; Tjordman
2000).
Several studies have prospectively assessed HPA axis function
following high-dose glucocorticoids during treatment for ALL.
Adrenal stimulation tests have been performed and repeated
until cortisol levels normalised. The majority of patients seem
to recover in a few weeks but prolonged suppression may oc-
cur, lasting over several months in some cases (Einaudi 2008;
Mahachoklertwattana 2004; Rix 2005). Since children with ALL
plus HPA axis suppression suffering from fever or other stressors
may benefit from glucocorticoid replacement therapy (e.g. hydro-
cortisone), it is important to derive a consistent picture of HPA
axis impairment after corticosteroid therapy.
Our aim was to undertake a systematic review of the HPA axis
function after glucocorticoid therapy for childhood ALL. On this
basis, adequate guidelines for glucocorticoid substitution can be
formulated and implemented to reduce the risk of infection in
childhood ALL.
O B J E C T I V E S
Primary objective
• To examine the occurrence of HPA axis suppression after
(each cycle of ) glucocorticoid therapy for childhood ALL.
• To examine the duration of HPA axis suppression after
treatment with glucocorticoids for childhood ALL.
Secondary objectives
To examine whether the HPA axis function after administration
of glucocorticoids is dependent on:
• the moment of testing after cessation of glucocorticoid
therapy
• the (cumulative) dose of glucocorticoids
• the type of glucocorticoids; prednisone, prednisolone or
dexamethasone
• the duration of glucocorticoid therapy
• the method of cessation of glucocorticoid therapy; abrupt
or gradual
M E T H O D S
Criteria for considering studies for this review
Types of studies
All study designs, except case reports and patient series with fewer
than 10 patients, examining the effect of glucocorticoid therapy
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for childhood ALL on HPA axis function. This effect can be eval-
uated both during treatment for ALL (after cessation of a gluco-
corticoid course) and after the end of all ALL treatment. Discrep-
ancies concerning the definition of a cohort study between review
authors were resolved by consensus. No third party arbitration was
needed.
Types of participants
Patients who were treated with glucocorticoids for ALL between
the age of 0 and 18 years, irrespective of the duration of follow-
up after the end of glucocorticoid therapy. Exclusion criteria are
cranial radiotherapy, since this may damage the HPA axis, and
testing HPA axis function by a CRH stimulation test only, since
this test is only indicated in patients with a central disorder of the
HPA axis (Maghnie 2005; Van Tijn 2008).
Types of interventions
Glucocorticoid therapy (prednisone, prednisolone, dexametha-
sone) during treatment for ALL. The intervention was not com-
pared to a control group, since this was not available (with the
exception of the included randomised controlled trials (RCT)).
Types of outcome measures
HPA axis function, measured by early morning plasma cortisol
levels (between 8 and 10 a.m.) or by stimulation tests (e.g. (low-
dose) ACTH stimulation test or glucagon stimulation test). We
used the cut-off limit as defined by the authors of the original
studies.
Search methods for identification of studies
See: Cochrane Childhood Cancer Group methods used in reviews
(Module CCG).
The objective of the literature search was to identify all studies,
except case reports and case series, reporting on HPA axis function
after glucocorticoid therapy for childhood ALL.
Electronic searches
We searched the following electronic databases: theCochraneCen-
tral Register of Controlled Trials (CENTRAL) (in The Cochrane
Library, issue 3, 2010), MEDLINE/PubMed (from 1945 to July
2010) and EMBASE/Ovid (from 1980 to July 2010). The search
strategies for the different electronic databases (using a combina-
tion of controlled vocabulary and text words) are shown in the
appendices (Appendix 1, Appendix 2, Appendix 3).
Searching other resources
We located information about trials not registered in CENTRAL,
MEDLINE or EMBASE, either published or unpublished, by
searching the reference lists of relevant articles and review articles.
We handsearched the conference proceedings of the International
Society for Paediatric Oncology (SIOP) (from 2005 to 2009) and
the American Society of Clinical Oncology (ASCO) (from 2005
to 2009). For the search strategy see Appendix 4.
We also scanned the International Standard Randomized Con-
trolled Trial Number (ISRCTN) register and the National In-
stitutes of Health (NIH) register for ongoing trials: http://
www.controlled-trials.com (both screened July 2010; for the
search strategy see Appendix 5).
We imposed no language restrictions. We will update the searches
every 2 years.
Data collection and analysis
Selection of studies
After performing the search strategy, two review authors indepen-
dently selected studies meeting the inclusion criteria. Discrepan-
cies between review authors were resolved by consensus. No third
party arbitration was needed. We obtained in full any study that
seemed to meet the inclusion criteria on grounds of the title or
abstract or both, for closer inspection. We clearly stated reasons
for exclusion of any study considered for this review.
Data extraction and management
Data extraction was performed by one review author using stan-
dardised forms and checked by another review author. The review
authors were not blinded to the journal, the authors or the insti-
tution. We extracted data on the following categories: study char-
acteristics, participants, interventions, outcome measures, length
of follow-up, risk factors, and ’Risk of bias’ assessment.
Discrepancies between authors were resolved by consensus. No
third party arbitration was needed.
Assessment of risk of bias in included studies
The assessment of risk of bias was based on previously described
checklists for observational studies according to Evidence-Based
Medicine Criteria (Grimes 2002; Laupacis 1994). The assessment
of risk of bias of the included studies was performed by one review
author and checked by another review author. The ’Risk of bias’
assessment criteria for observational studies are described in Table
1. For RCTs we used the ’Risk of bias’ items as described in the
module of the Childhood Cancer Group, which are based on the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2009; Module CCG) (see Table 2). Discrepancies between review
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authors were resolved by consensus. No third party arbitration was
needed.
Measures of treatment effect
Prevalence of HPA axis suppression at several follow-up time
points and time duration of HPA axis suppression.
Dealing with missing data
We contacted authors of individual studies for clarification of un-
clear data or to obtain missing data regarding selection of studies,
the ’Risk of bias’ assessment and data extraction.
Assessment of heterogeneity
We planned to assess heterogeneity both by visual inspection of
the forest plots and by a formal statistical test for heterogeneity,
that is the I2 statistic. However, since we were not able to pool the
results of the included studies, this was not applicable.
Assessment of reporting biases
We planned to use a funnel plot to quantify the potential presence
of publication bias. However, since we were not able to pool the
results of the included studies, this was not applicable.
Data synthesis
Weplanned toperformanalyses using the statistical softwareCom-
prehensive Meta Analysis (Biostat, Inc, USA).
Across the various studies, we planned to conduct a multivariate
linear meta-regression analysis model with a backwards selection
strategy (P < 0.10) to examine the relation between potential pre-
dictive factors and HPA axis suppression.
However, since we were not able to pool the results of the included
studies, this was not applicable and we described the results of the
individual studies separately. Kaplan-Meier curves were calculated
using SPSS version 15.0.
Sensitivity analysis
We planned to perform a sensitivity analysis for the used ’Risk of
bias’ assessment criteria. However, since we were not able to pool
the results of the included studies, this was not applicable.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
Running the searches in the electronic databases of CENTRAL,
MEDLINE/PubMed and EMBASE/Ovid revealed a total of 1388
references. Initial screening of the titles and abstracts excluded
1375 references that clearly did not fulfil all criteria for considering
studies for this review.Of the remaining13 referenceswe examined
the full-text articles. Seven of the 13 full-text articles were eligible
for inclusion in this systematic review, whereas the other six were
not. The reasons for exclusion are illustrated in Characteristics of
excluded studies.
Scanning the reference list of relevant articles and reviews did not
identify any additional eligible studies.
Scanning the conference proceedings of SIOP and ASCO did
not identify any eligible studies and scanning the ongoing trials
databases did not identify any ongoing studies.
In summary, seven articles could be included in this review. We
made attempts to contact authors to clarify aspects of the study
design and data analysis. Characteristics of the included studies
are summarised in the Characteristics of included studies table.
Included studies
All included studies evaluated adrenal function after glucocorti-
coid therapy for childhood ALL. None of the studies assessed the
HPA axis at the level of the hypothalamus, pituitary or both. The
total number of patients included in the studies was 189. The
seven included studies examined the adrenal function after differ-
ent types, doses and durations of glucocorticoid therapy and after
different methods of cessation of glucocorticoid therapy. Three
studies examined the effect of dexamethasone on adrenal function
(Cunha 2004; Felner 2000; Kuperman 2001) and four studies
evaluated the effect of both dexamethasone and predniso(lo)ne
on adrenal function (Einaudi 2008; Mahachoklertwattana 2004;
Petersen 2003; Rix 2005). Adrenal function was measured by early
morning plasma cortisol levels (between 8 and 10 a.m.) (Cunha
2004; Kuperman 2001) or by the (low-dose) ACTH stimula-
tion test (Einaudi 2008; Felner 2000;Mahachoklertwattana 2004;
Petersen 2003; Rix 2005). Four studies performed follow-up tests
until normalisation of adrenal function (Einaudi 2008; Felner
2000; Mahachoklertwattana 2004; Petersen 2003), for the other
three studies the follow-up lengths were 1month, 2 weeks and 2 to
7 days, respectively (Cunha 2004; Kuperman 2001; Rix 2005). Six
of the seven identified studies were observational studies (Cunha
2004; Felner 2000; Kuperman 2001;Mahachoklertwattana 2004;
Petersen 2003; Rix 2005) and one was an RCT evaluating pred-
nisolone versus dexamethasone (both treatment groups received
prednisolone prior to randomisation) (Einaudi 2008).
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Excluded studies
Information on the six studies excluded during examination of
the full-text articles is included in the Characteristics of excluded
studies table. Themost common reasons for exclusion were cranial
irradiation therapy or the lack of (adequate) HPA axis function
tests.
Risk of bias in included studies
Cohort studies
For the evaluation of the ’internal validity’ of the six included co-
hort studies we assessed the risk of selection bias, attrition bias,
detection bias and confounding that was present in the included
studies. Based on additional information provided by the authors,
there was a low risk of selection bias (based on the representative-
ness of the study group) in four of the six studies as the study group
consisted of more than 90% of the original cohort (Felner 2000;
Kuperman 2001; Petersen 2003; Rix 2005). According to addi-
tional information provided by the authors, one study selected an
unrepresentative study group of about 30% of the original cohort
(Cunha 2004). For another study neither the article nor the corre-
spondence with the author provided information on the selection
of the participants (Mahachoklertwattana 2004). The risk of attri-
tion bias (based on the completeness of follow-up) was low in all six
studies as the outcome was assessed for 60% to 90% of the study
group at the end date of the study (Cunha 2004; Felner 2000;
Kuperman 2001; Mahachoklertwattana 2004; Petersen 2003; Rix
2005). Additional information provided by the authors of one
study reported that the outcome assessor was not blinded (Rix
2005). None of the other studies provided information on the
blinding of the outcome assessor to glucocorticoid treatment, so
detection bias could not be ruled out. In five studies, confounding
(based on important risk factors and follow-up that were taken
into account) might have been present (Cunha 2004; Felner 2000;
Kuperman 2001; Mahachoklertwattana 2004; Rix 2005). In one
study, fluconazole therapy as a risk factor for the development of
adrenal insufficiency was taken into account (Petersen 2003).
For the evaluation of the ’external validity’ of the included cohort
studies we assessed the risk of reporting bias. In four studies, the
study group was well defined in terms of treatment protocol and
(cumulative) dose, type, duration and form of cessation of glu-
cocorticoid treatment (Cunha 2004; Mahachoklertwattana 2004;
Petersen 2003; Rix 2005). Two studies did not mention the treat-
ment protocol (Felner 2000;Kuperman2001). In all six studies the
follow-up was well defined as the length of follow-up and the fre-
quency of measuring was mentioned (Cunha 2004; Felner 2000;
Kuperman 2001; Mahachoklertwattana 2004; Petersen 2003; Rix
2005). In these studies the outcomewaswell defined and themeth-
ods of detection were described and the outcome definition was
objective and precise (Cunha 2004; Felner 2000; Kuperman 2001;
Mahachoklertwattana 2004; Petersen 2003; Rix 2005). The risk
estimation (based on the calculation of relative risk, odds ratio, at-
tributable risk, linear or logistic regressionmodel,mean difference,
or Chi2 statistic) was well defined in five of the six studies (Cunha
2004; Felner 2000; Kuperman 2001;Mahachoklertwattana 2004;
Rix 2005).
See also Table 3.
Randomised controlled trial
For the included RCT we evaluated the risk of selection bias, per-
formance bias, detection bias, attrition bias, reporting bias and
other biases. Based on additional information provided by the au-
thors, no selection bias (based on sequence generation and con-
cealment of allocation) was present (Einaudi 2008). Performance
bias (based on the blinding of care providers and participants) and
detection bias (based on the blinding of the outcome assessors)
could not be ruled out (Einaudi 2008). The RCT was susceptible
for reporting bias as not all of the study’s pre-specified primary
outcomes were reported (Einaudi 2008). The risk on attrition bias
(based on the completeness of outcome data) or other bias (i.e.
based on potential source of bias related to the specific study de-
sign, premature termination of the study due to some data-depen-
dent process, extreme baseline imbalance) in the RCT was low
(Einaudi 2008).
See also Table 4.
Effects of interventions
Adrenal insufficiency (occurrence and duration)
Data on the prevalence and the duration of adrenal insufficiency
after treatment with glucocorticoid therapy for childhood ALL
could be extracted from all included studies. However, it should be
noted that the individual studies used different types and (cumu-
lative) doses of glucocorticoids. In addition, differences in dura-
tion and method of cessation of glucocorticoid therapy occurred.
Methods of testing adrenal function varied as well. Due to this
heterogeneity pooling of results was not possible. For more infor-
mation see Characteristics of included studies.
Two studies used the ACTH stimulation test with comparable
cut-off limits (stimulated cortisol: 18 µg/dL (500 nmol/L)) for
measuring adrenal function (Felner 2000; Petersen 2003). Before
glucocorticoid therapy, adrenal function was normal in all patients
in the study of Felner 2000. However, all 10 patients (100%) had
insufficient cortisol levels 1 day after abrupt cessation of 28 days of
dexamethasone at 6 mg/m2/day. Three out of 10 patients (30%)
had ongoing adrenal insufficiency after 4 weeks but all recovered
after 8 weeks. In the study of Petersen 2003, two types of glu-
cocorticoid therapy were assessed; induction therapy comprising
35 days of prednisolone 60 mg/m2/day with tapering over 9 days
and re-induction therapy comprising 21 days of dexamethasone
10 mg/m2/day with tapering over 9 days. Re-induction therapy
succeeded induction therapy, thus patients in the dexamethasone
group also received induction therapy with prednisolone. HPA
axis function was not assessed before glucocorticoid therapy. Af-
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ter induction therapy (n = 10), seven out of 10 patients (70%)
had adrenal insufficiency within the first week. Six patients (60%)
had ongoing adrenal insufficiency after 3 weeks and four patients
(40%) after 7 weeks. These four patients remained insufficient at
the end of their follow-up, that is after 10, 11, 11 and 19 weeks,
respectively. The latter patient, with no recovery by 19 weeks, re-
ceived, in addition to the induction therapy, two 1-week long re-
induction courses including prednisolone 60 mg/m2/day during
adrenal insufficiency. After re-induction therapy (n = 7), five out
of seven patients (71%) had adrenal insufficiency within the first
week. Four patients (57%) had ongoing adrenal insufficiency af-
ter 3 weeks and three patients (43%) after 7 weeks. These three
patients remained insufficient at the end of their follow-up, that is
after 16, 33 and 34 weeks, respectively. One of these patients, with
no recovery after 16 weeks, received an additional 1-week long re-
induction course of prednisolone 60mg/m2 /day during the period
of adrenal insufficiency. The other two patients, with no recovery
after 33 and 34 weeks, received three additional 1-week long re-
induction courses including prednisolone 60 mg/m2/day during
adrenal insufficiency. See Table 5 for an overview and Figure 1 for
the Kaplan-Meier curve of the prevalence and duration of adrenal
insufficiency in the studies that used an ACTH suppression test.
Figure 1. Kaplan-Meier estimate of prevalence and duration of adrenal insufficiency after treatment with
glucocorticoid therapy for childhood acute lymphoblastic leukaemia based on ACTH stimulation tests.
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Three studies used the low-dose ACTHstimulation test with com-
parable cut-off limits (stimulated cortisol: 18 µg/dL (500 nmol/
L)) for measuring adrenal function (Mahachoklertwattana 2004;
Rix 2005; Einaudi 2008). In the study of Mahachoklertwattana
2004 all patients received induction therapy with prednisolone 40
mg/m2/day. Four weeks after its completion this was followed by
maintenance therapy every 4 weeks consisting of 7 days of dexam-
ethasone 8 mg/m2/day. Baseline cortisol levels before induction
therapy and 2 weeks afterwards were not significantly different be-
tween the adrenal suppressed and the unsuppressed group. Eleven
out of 24 patients (46%) had adrenal insufficiency 2 weeks after
abrupt cessation of 28 days of induction therapy. Nine patients
(38%) had ongoing adrenal insufficiency after 4 weeks, seven pa-
tients (29%) after 8weeks and three patients (13%) after 12weeks.
The latter three patients remained insufficient at the end of follow-
up at 20 weeks.
In the study of Rix 2005, three types of glucocorticoid treatment
were evaluated. All patients (standard risk, intermediate risk and
high risk) received induction therapy (22 patients in total were
tested afterwards; for two patients no information was available)
comprising 35 days of prednisolone 60 mg/m2/day with taper-
ing over 9 days. All patients also received 7-day courses of pred-
nisolone 60mg/m2/daywithout tapering (13 patients in total were
tested afterwards) and intermediate-risk and high-risk patients re-
ceived additionally 21 days of dexamethasone 10 mg/m2/day with
tapering over 9 days (7 patients in total were tested afterwards).
The 7-day course of prednisolone and the dexamethasone course
followed induction therapy. The intermediate-risk group received
the dexamethasone course before the 7-day course of prednisolone
and the high-risk group received the dexamethasone course after
the 7-day course of prednisolone. Based on additional information
provided by the authors, 13 patients were tested before induction
therapy, and all had a normal adrenal function. Sixteen patients
out of 22 (73%) had adrenal insufficiency 1 day after cessation
of induction therapy; one of them was lost to follow-up there-
after. Five out of 22 patients (23%) were not tested at this time
point. Eight patients (36%) had ongoing adrenal insufficiency af-
ter 3 days; two of them were lost to follow-up afterwards. Seven
patients (32%) (including the patient that was lost to follow-up)
with no confirmed adrenal recovery were not tested at this time
point. Eight patients (36%) had ongoing adrenal insufficiency at
the end of follow-up of 5 days. Three patients (14%) (i.e., the three
patients that were lost to follow-up) with no confirmed adrenal
recovery were not tested at this time point. After 7-day courses of
prednisolone, all 13 patients (100%) remained insufficient at the
end of the follow-up period of 2 days. However, two patients out
of 13 (15%) already had an insufficient adrenal function before
prednisolone therapy. Five patients out of seven (71%) underwent
a low-dose ACTH test before dexamethasone therapy; all patients
had sufficient cortisol levels. One day after the dexamethasone
course, two out of seven patients (29%) had adrenal insufficiency;
one of them was lost to follow-up thereafter. Five out of seven
patients (71%) were not tested at this time point. Three patients
(43%) had ongoing adrenal insufficiency after 3 days; one of them
was lost to follow-up afterwards. Two patients (29%) (including
the patient that was lost to follow-up) with no confirmed adrenal
recovery were not tested at this time point. One patient (14%) had
ongoing adrenal insufficiency at the end of the follow-up period
of 7 days. Two patients (29%) (i.e., the two patients that were lost
to follow-up) with no confirmed adrenal recovery were not tested
at this time point.
In the study of Einaudi 2008, two randomised arms of glucocor-
ticoid therapy were examined; 22 days of prednisolone 60 mg/
m2/day with tapering over 9 days (n = 40) and 22 days of dex-
amethasone 10 mg/m2/day with tapering over 9 days (n = 24).
Both groups of patients received 7 days of prednisolone 60 mg/m
2/day in advance. At diagnosis, basal cortisol values were within
the normal range in all patients. In the prednisolone arm, 32 out
of 40 patients (80%) had adrenal insufficiency 1 day after cessa-
tion of glucocorticoid therapy, eight patients (20%) had ongoing
adrenal insufficiency after 7 to 14 days (in the KaplanMeier curve
marked as 14 days) and five patients (13%) after 28 days. All pa-
tients (100%) recovered in 10 weeks (in the Kaplan Meier curve
marked as 10 weeks). In the dexamethasone arm, 20 out of 24
patients (83%) had adrenal insufficiency 1 day after cessation of
glucocorticoid therapy. Four patients (17%) had ongoing adrenal
insufficiency after 7 to 14 days (in the KaplanMeier curve marked
as 14 days) and three patients (13%) after 28 days. All patients
(100%) recovered in 10 weeks (in the Kaplan Meier curve marked
as 10 weeks). See Table 6 for an overview and Figure 2 for the
Kaplan-Meier curve of the prevalence and duration of adrenal in-
sufficiency in the studies that used a low-dose ACTH test.
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Figure 2. Kaplan-Meier estimate of prevalence and duration of adrenal insufficiency after treatment with
glucocorticoid therapy for childhood acute lymphoblastic leukaemia based on low-dose (LD) ACTH
stimulation tests.
Two studies used basal morning cortisol values for measuring
adrenal function. In the study of Cunha 2004, including 35 chil-
dren, median basal cortisol levels were inhibited on the 8th day
(1.2 µg/dL, range 0.9 to 132.7 µg/dL) and the 28th day (0.9 µg/
dL, range 0.9 to 6.6 µg/dL) of 28 days of dexamethasone 6mg/m2 /
day and 48 hours after cessation (over 10 days) of dexamethasone
treatment (2.4 µg/dL, range 0.9 to 11.2 µg/dL) compared to pre-
glucocorticoid therapy levels (17.5 µg/dL, range 7.6 to 40.9 µg/
dL) (P = 0.01 for the three tests versus pre-glucocorticoid levels).
Median basal cortisol levels 1 month after cessation of dexametha-
sone treatment (12.4 µg/dL, range 1.8 to 29.0 µg/dL), although
slightly lower, did not show a significant difference compared with
pre-glucocorticoid therapy levels. No data on patient level were
available.
In the study of Kuperman 2001, including 15 children,mean basal
cortisol levels (± standard error of the mean) were significantly (P
< 0.05) lower on day 7 (10.8 ± 1.0 µg/dL) and day 14 (11.5 ± 2.0
µg/dL) after abrupt cessation of 42 days of dexamethasone 6 mg/
m2/day than pretreatment (17.8 ± 1.3 µg/dL). Levels at day 7 and
day 14 did not differ significantly. Based on additional informa-
tion provided by the authors, all patients (100%) had sufficient
basal cortisol levels at diagnosis (> 7 µg/dL), whereas four out of
15 (27%) patients had insufficient basal cortisol levels 7 days after
cessation of dexamethasone therapy. One patient was lost to fol-
low-up thereafter. Fourteen days after cessation of dexamethasone
therapy, four (29%) out of 14 patients had insufficient basal cor-
tisol levels. It should be noted that one of them had a sufficient
basal cortisol level 7 days earlier. Therefore, these data could not
be presented in a Kaplan-Meier curve.
See Table 7 for an overview of the prevalence and duration of
adrenal insufficiency in the studies that used basalmorning cortisol
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values.
Other outcome measures
Identifying whether the adrenal function after administration of
glucocorticoids was dependent on the moment of testing, the (cu-
mulative) dose, type or duration of glucocorticoid therapy or the
method of cessation of glucocorticoid therapy was not possible
due to the heterogeneity.
D I S C U S S I O N
With the improvement of survival of childhood ALL, treatment-
related side effects become increasingly relevant. Glucocorticoids
play an important role in the treatment of childhood ALL, but
supraphysiological doses may suppress the HPA axis, resulting in
an impaired stress response and an inadequate defence against in-
fections (Henzen 2000; Krasner 1999). Patients with HPA axis
suppression may benefit from glucocorticoid replacement therapy
(e.g. hydrocortisone) to reduce the risk of life-threatening compli-
cations. Unfortunately, little information is known on the occur-
rence and duration of HPA axis suppression and adequate guide-
lines for glucocorticoid substitution are lacking. This is the first
systematic review evaluating HPA axis function after treatment
with glucocorticoid therapy for childhood ALL.
We identified seven studies evaluating adrenal function after treat-
ment with glucocorticoid therapy for childhood ALL, including
one RCT. None of the studies evaluated the HPA axis at the level
of the hypothalamus, pituitary, or both. Due to the substantial dif-
ferences in types and (cumulative) doses of glucocorticoids used,
in duration and method of cessation of glucocorticoid therapy and
in method of testing adrenal function, pooling of results was not
possible. The included studies demonstrated that adrenal insuf-
ficiency occurs in nearly all patients in the first days after cessa-
tion of glucocorticoid treatment for childhood ALL. The majority
of patients recovered from adrenal insufficiency within 7 weeks.
However, a small amount of patients had ongoing adrenal insuf-
ficiency lasting up to 34 weeks. At first impression, no significant
differences in the occurrence and duration of adrenal insufficiency
between different types, (cumulative) doses, durations and meth-
ods of cessation of glucocorticoid therapy were present, but due to
the heterogeneity between studies we were not able to assess this
further.Due to this, and the small patient numbers in the included
studies (i.e. low power), definitive conclusions cannot thus not
be provided. Only one study was designed as an RCT, enabling
comparison between two different types of glucocorticoid therapy;
prednisolone versus dexamethasone (Einaudi 2008). Both treat-
ment groups received prednisolone prior to the randomised treat-
ment. The occurrence and duration of adrenal insufficiency did
not differ between the treatment arms.
Previous studies demonstrated adrenal suppression after high-dose
fluconazole therapy (Albert 2001; Shibata 2001). Only one of the
studies that was included in this review, reported on fluconazole
therapy (Petersen 2003). In this study, two of the three patients
receiving fluconazole had ongoing adrenal insufficiency 8 months
after cessation of dexamethasone therapy, whereas the third pa-
tient recovered after 3 weeks. It should be taken into account that
fluconazole therapy may have influenced the duration of adrenal
insufficiency in these patients.
Due to the paucity of RCTs on HPA axis suppression after glu-
cocorticoid therapy in childhood ALL, the majority of studies in-
cluded in this systematic review were uncontrolled studies. Only
one RCT was identified. Due to the lack of control groups it
was impossible to evaluate possible causes of HPA axis suppres-
sion other than glucocorticoid therapy. Furthermore, all included
studies used biochemicalmarkers to evaluate adrenal insufficiency;
they did not discuss the clinical consequences of adrenal insuffi-
ciency. All included studies had methodological limitations, but
currently, this is the best available evidence on this topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on the currently available evidence, we can conclude that
adrenal insufficiency in the first days after cessation of glucocor-
ticoid therapy for childhood ALL routinely occurs, but the exact
duration of adrenal insufficiency remains unclear. Since no data
on the level of the hypothalamus and the pituitary were available
we cannot make any conclusions regarding those outcomes. The
majority of patients seem to recover within 3 days to 7 weeks.
However, a small number of patients have prolonged adrenal in-
sufficiency, persisting up to several months. Clinicians should con-
sider prescribing glucocorticoid replacement therapy (e.g. hydro-
cortisone) during periods of serious stress in the first weeks after
cessation of glucocorticoid therapy for childhood ALL, to reduce
the risk of life-threatening complications. If replacement therapy
is indicated, the beneficial effects and side effects should be eval-
uated. Until results of adequate future studies on the incidence
and duration of HPA axis suppression are available, an HPA axis
stimulation test can be recommended , for example, 2 months af-
ter cessation of glucocorticoids, to determine if the HPA axis has
recovered and if replacement therapy during periods of stress can
be discontinued. Exclusively morning cortisol levels are inappro-
priate to evaluateHPA axis recovery because they only reflect basal
cortisol prediction and not the ability of the HPA axis to respond
to stress (Agwu 1999).
Special attention should be paid to patients receiving fluconazole
therapy, and perhaps similar antifungal drugs, as this may prolong
the duration of adrenal insufficiency.
No definitive conclusions regarding differences in the occurrence
and duration of adrenal insufficiency between the type (pred-
niso(lo)ne versus dexamethasone), (cumulative) dose, duration
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and method of cessation (abrupt or gradual) of glucocorticoid
therapy can be made.
Implications for research
Studies examining HPA axis suppression after high-dose gluco-
corticoid therapy for childhood ALL are scarce, especially RCTs.
High-quality research regarding the occurrence and duration of
HPA axis suppression after glucocorticoid therapy for childhood
ALL is needed in order to formulate adequate evidence-based
guidelines for glucocorticoid replacement therapy. It will also be
of interest to compare the serious adverse effects in patients with,
and without, persistent HPA axis suppression. In addition, there
is a need for studies evaluating the long-term effects of glucocor-
ticoid therapy on the HPA axis.
Future studies should focus on identifying differences in the ef-
fect of type, (cumulative) dose, repeated exposure, duration and
method of cessation of glucocorticoid therapy on the occurrence
and duration of HPA axis suppression. The number of included
patients should be sufficient to obtain the power needed for reli-
able results.
Furthermore, an interesting and relevant topic for future research
would be the (genetic) susceptibility of individuals for HPA axis
suppression after glucocorticoid treatment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cunha 2004
Methods Study type: prospective multicentre study
Setting: Brazil (University Hospital of Federal University of Minas Gerais, Santa Casa de Misericórdia and Hospital
Felício Rocho, Belo Horizonte). This information was based on additional information provided by the authors
Participants 35 children (median age at diagnosis/first HPA axis function test 6.9 years (range 1.2 to 14.4 years); 17 boys and 18
girls) with ALL
Interventions Treatment according to the Brazilian Group for Treatment of ALL, 1993 protocol (GBTLI-93). Specific medication
not defined
Type of glucocorticoid therapy: dexamethasone (6 mg/m2/day, twice daily) given for 28 days
Cumulative dexamethasone dose 183.75 mg/m2
Duration of glucocorticoid therapy: 28 days + 9 days’ tapering doses (in total 37 days)
Methods of cessation of glucocorticoid therapy: dose reduction over 10 days (50% each 3 days, with complete
withdrawal on the 10th day)
No control intervention
Outcomes Specific HPA axis function test: the ovine CRH stimulus test at 8 a.m. (after an overnight fasting period), including
cortisol basal morning value
Moment of testing: before introduction of dexamethasone, on the 8th day and the 28th day of dexamethasone use,
and 48 hours and 1 month after cessation of dexamethasone. The tests were performed during treatment for ALL
Cut-off limits defined by original studies: baseline cortisol: 5 to 25 µg/dL (138.9 to 694.4 nmol/L) and stimulated
cortisol levels were compared with the levels before treatment
Notes 7 patients were lost to follow-up at the 8th and 28th test day, 1 more 48 hours after glucocorticoid therapy test and
7 more 1 month after glucocorticoid therapy test
Length of follow-up after glucocorticoid therapy: 1 month
Risk factors were not evaluated
Einaudi 2008
Methods Study type: multicentre RCTSetting: Department of Pediatric Onco-Hematology, University of Turin, Italy and
Department of Pediatrics, University of Milano-Bicocca, Hospital of Monza, Italy. This information was based on
additional information provided by the authors
Participants 64 children (24 patients that received dexamethasone: mean age at diagnosis 4 years 11 months (range 1 year 2
months to 12 years 1 month), 11 boys and 13 girls; 40 patients that received prednisone: mean age at diagnosis 6
years 9 months (range 1 year 2 months to 17 years 6 months), 18 boys and 22 females) with ALL. This information
was based on additional information provided by the authors
Interventions Treatment according to the AIEOP ALL 2000 study. Induction phase IA: prednisone (from day 8 randomisation
prednisone or dexamethasone), vincristine, daunorubicin, Escherichia coli L-asparaginase and intrathecal methotrex-
ate. Induction phase IB: 6-mercaptopurine, cyclophosphamide, cytosine-arabinoside and intrathecal methotrexate
Type of glucocorticoid therapy: induction phase: oral prednisone (60 mg/m2/day, divided into 3 daily doses) given on
days 1 to 7. On day 8 the children were randomised to receive either dexamethasone (10 mg/m2/day) or prednisone
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(60 mg/m2/day) both divided into 3 oral doses until day 29. From day 30 onwards, the dose of both corticosteroids
was tapered by 50% every 3 days, until complete withdrawal over 9 days
Cumulative dose of glucocorticoid therapy: prednisone 420 mg/m2 + dexamethasone 246.25 mg/m2 or prednisone
1477.50 mg/m2
Duration of glucocorticoid therapy: prednisone 7 days + dexamethasone 22 days or prednisone 22 days + 9 days’
tapering doses (in total 39 days)
Methods of cessation of glucocorticoid therapy: dose was tapered by 50% every 3 days, until complete withdrawal
over 9 days
Outcomes Specific HPA axis function test: basal cortisol between 8 and 9 a.m. at diagnosis and the low-dose ACTH test between
8 and 11 a.m. (1 µg/1.74 m2 of tetracosactrin (Synacthen, Novartis, Basal, Switzerland), basal morning value cortisol,
after 30 and 60 minutes)
Moment of testing: at diagnosis basal cortisol was determined. The first low-dose ACTH stimulation test was
performed 24 hours after the last tapering dose of glucocorticoid (on day 39), which was given as a single dose in the
morning. The tests were performed during treatment for ALL
Cut-off limits defined by original studies: basal cortisol: 6 to 30 µg/dL (167 to 833 nmol/L). Low-dose ACTH test:
normal response ≥ 18 µg/dL (≥ 500 nmol/L)
Notes 0 patients were lost to follow-up
Length of follow-up after glucocorticoid therapy: patients with suppressed levels underwent further low-dose ACTH
tests between 7 and 14 days from the last glucocorticoid dose and every 2 weeks thereafter until cortisol levels
normalised. The total follow-up duration was 10 weeks
Risk factors were not evaluated
Felner 2000
Methods Study type: prospective single-centre study
Setting: Children’s Medical Center of Dallas (University of Texas Southwestern Medical School). This information
was based on additional information provided by the authors
Participants 10 children (mean age at diagnosis 5.3 ± 2.9 years (range 2.0 to 9.9 years); 7 boys and 3 girls) with early B-cell lineage
ALL
Interventions Induction therapy: dexamethasone, vincristine, L-asparaginase and daunorubicin. High-risk therapy: 1 additional
lumbar puncture with intrathecal chemotherapy during induction
Type of glucocorticoid therapy: induction phase: oral dexamethasone (6 mg/m2/day, divided into 2 daily doses) for
28 consecutive days
Cumulative dexamethasone dose 168 mg/m2
Duration of glucocorticoid therapy: 28 days
Methods of cessation of glucocorticoid therapy: abrupt
No control intervention
Outcomes Specific HPA axis function test: 250 µg cosyntropin stimulation test (synthetic corticotrophin 1-24 / ACTH test) iv
between 8 and 10 a.m. (Cotrosyn, Organon) (basal morning value cortisol and after 45 minutes)
Moment of testing: at diagnosis (baseline), 24 hours after completion of the dexamethasone course and every 4 weeks
thereafter until normalisation of adrenal function. The tests were performed during treatment for ALL
Cut-off limits defined by original studies: baseline cortisol: not defined. Low-dose ACTH test: normal response ≥
18 µg (≥ 500 nmol/L)
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Felner 2000 (Continued)
Notes 0 patients were lost to follow-up
Length of follow-up after glucocorticoid therapy: patients with suppressed levels underwent further tests every 4
weeks thereafter until cortisol levels normalised. The total follow up duration was 8 weeks
Risk factors were not evaluated
Kuperman 2001
Methods Study type: prospective single-centre study
Setting: The Oncology Department of the Children’s Institute, Hospital das Clinicas-Sao Paulo University School
of Medicine, Brazil
Participants 15 children (age at diagnosis 5 months to 12 years; 5 boys and 10 girls) with ALL
Interventions Dexamethasone, daunomycin, vincristine, L-asparaginase and cytosine-arabinoside
Type of glucocorticoid therapy: induction phase: oral dexamethasone (6 mg/m2/day, divided into 3 daily doses) for
42 consecutive days
Cumulative dexamethasone dose 252 mg/m2
Duration of glucocorticoid therapy: 42 days
Methods of cessation of glucocorticoid therapy: abrupt
No control intervention
Outcomes Specific HPA axis function test: 1 µg/kg ovine CRH stimulation test iv, after an 8-hours fast, between 8 and 9 a.m.
(basal morning value cortisol and after 15, 30, 60 and 90 minutes)
Moment of testing: before dexamethasone therapy (baseline), 7 and 14 days after the last dose of dexamethasone. It
was not defined if tests were performed during treatment for ALL
Cut-off limits defined by original studies: basal cortisol: 7.0 µg/dL. This information was based on additional
information provided by the authors. Ovine CRH test: cortisol above 12.8 µg/dL (353.2 nmol/L) was considered
normal (basal and peak cortisol levels of the 3 different time points were compared with each other)
Notes Based on additional information provided by the authors, 1 patient was lost to follow-up 14 days after administration
of dexamethasone
Length of follow-up after glucocorticoid therapy: 14 days
Risk factors were not evaluated
Mahachoklertwattana 2004
Methods Study type: prospective single-centre study
Setting: Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand
Participants 24 children (median age at diagnosis 3.5 years (range 1 to 14 years); 13 boys and 11 girls) with newly diagnosed ALL
Interventions According to themodificationof St JudeChildren’sResearchHospital Total XIII Protocol for ALL. Standard induction
therapy: prednisolone, vincristine, L-asparaginase, doxorubicin, etoposide and cytosine-arabinoside
Type of glucocorticoid therapy: induction phase: oral prednisolone (40 mg/m2/day, divided into 3 daily doses) for
28 consecutive days. 4 weeks after completion of the induction therapy, the patients received maintenance therapy
consisting of a 7-day course of high-dose dexamethasone 8 mg/m2/day, every 4 weeks in conjunction with other
chemotherapeutic agents according to the risk classification
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Cumulative prednisolone dose 1120 mg/m2. Cumulative dose of dexamethasone per patient depended on how long
the patient was followed up. A dexamethasone course (56 mg/m2/day) was administrated at 4, 8, 12 and 16 weeks
after induction therapy. The maximum cumulative dose of dexamethasone (4 courses) is 224 mg/m2
Duration of glucocorticoid therapy: 28 days of prednisolone and additional 7-day course of dexamethasone
Methods of cessation of glucocorticoid therapy: abrupt
No control intervention
Outcomes Specific HPA axis function test: serum cortisol level at 8 a.m., at diagnosis (baseline) and low-dose ACTH stimulation
test (1 µg cosyntropin, Cotrosyn, Organon, West Orange, NJ) at 8 a.m. after an overnight fast (basal cortisol and
after 30 minutes)
Moment of testing: baseline adrenal function was assessed by determination of serum cortisol level at 8 a.m. be-
fore induction therapy. The first low-dose ACTH stimulation test was performed 2 weeks after discontinuation of
prednisolone. Patients with adrenal insufficiency underwent repeated ACTH tests 4 weeks after completion of the
prednisolone course and every 4 weeks thereafter in the morning of the day in which the patients were admitted for
the next course of maintenance chemotherapy until normalisation. The tests were performed during treatment for
ALL
Cut-off limits defined by original studies: basal cortisol: not defined. Low-dose ACTH test: normal response ≥ 18
µg/dL (≥ 500 nmol/L)
Notes 0 patients were lost to follow-up
Length of follow-up after glucocorticoid therapy: up to 20 weeks
Risk factors were not evaluated
Petersen 2003
Methods Study type: prospective single-centre study
Setting: The University Hospital, Rigshospitalet, Copenhagen, Denmark
Participants 17 children (median age at diagnosis 5.4 years (range 2 to 15 years)) with ALL
Interventions According to the risk group by theNOPHOALL-1992 or ALL-2000 protocol. 10 patients were studied after receiving
prednisolone, weekly vincristine, 4 doses of intrathecal methotrexate, L-asparaginase and doxorubicin. 7 additional
patients were studied following re-induction therapy with dexamethasone, weekly vincristine and daunorubicin, 4
doses of L-asparaginase and intrathecal methotrexate
Type of glucocorticoid therapy: induction phase (n = 10): prednisolone (60 mg/m2/day, in 3 daily doses) during the
first 5 weeks of induction therapy followed by 9 days of tapering. 1-week courses of prednisolone (60 mg/m2/day,
based on additional information provided by the authors) were administered every 4 to 10 weeks as part of the re-
induction therapy, beginning approximately 8 weeks after prednisolone
Re-induction therapy (n = 7): dexamethasone (10 mg/m2/day, divided in 3 daily doses) for 3 weeks on protocol days
169 to 190 (4 intermediate-risk patients) or days 246 to 267 (3 high-risk patients) followed by 9 days of tapering.
The high-risk patients received two 1-week courses of prednisolone (40 mg/m2/day) 4 and 8 weeks prior to the
dexamethasone therapy. 1-week courses of prednisolone (60 mg/m2/day) were administered every 4 to 10 weeks as
part of the re-induction therapy, beginning approximately 11 weeks after dexamethasone therapy
Cumulative dose: induction therapy: 2100 mg/m2 + 157.5 mg/m2 prednisolone. 1 patient received additional 840
mg/m2 prednisolone during the period of adrenal insufficiency. Re-induction therapy: 210 mg/m2 + 26.5 mg/m2
dexamethasone. High-risk patients received 560 mg/m2 prednisolone in advance 1 patient received an additional
420 mg/m2 prednisolone during the period of adrenal insufficiency and 2 patients received an additional 1260 mg/
m2 prednisolone during the period of adrenal insufficiency
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Duration of glucocorticoid therapy: induction therapy: 35 days of prednisolone + 9 days’ tapering doses. 1 patient
received an additional 14 days of prednisolone. Re-induction therapy: 21 days of dexamethasone + 9 days’ tapering
doses. The high-risk patients received 14 days of prednisolone 4 and 8 weeks prior to dexamethasone therapy. After
the dexamethasone course, the high-risk patients also received prednisolone for 1 week (n = 1) or 3 weeks (n = 2)
Methods of cessation of glucocorticoid therapy: 50% each 3 days, over 9 days in total
No control intervention
Outcomes Specific HPA axis function test: ACTH stimulation test (250 µg tetracosactide (Synacthen, Novartis) between 8 and
11 a.m. (basal cortisol and after 30 and 60 minutes)
Moment of testing: the adrenal function was assessed by an ACTH stimulation test within 2 weeks after discontin-
uation of glucocorticoid therapy. The test was repeated every 3 to 5 weeks until recovery or end of follow-up. The
tests were performed during treatment for ALL
Cut-off limits defined by original studies: low-dose ACTH test: normal response > 500 nmol/L
Notes No patients were lost to follow-up
Length of follow-up after glucocorticoid therapy: fluctuating
Fluconazole therapy as a risk factor for adrenal insufficiency was evaluated
Rix 2005
Methods Study type: prospective multicentre study
Setting: Department of pediatrics, Aalborg University Hospital and the department of pediatrics, Aarhus University
Hospital Skejby. This information was based on additional information provided by the authors
Participants 24 children (median age at diagnosis 4.5 years (range 1.8 to 14.6 years); 17 boys and 7 girls) with newly diagnosed
ALL. 12 had standard-risk ALL according to the Nordic risk criteria, 7 had intermediate risk and 5 had high risk
Interventions According to the NOPHO ALL-92 protocol
Type of glucocorticoid therapy: all children received prednisolone (60 mg/m2/day, in 3 daily doses) during the first
5 weeks of induction therapy followed by 9 days of tapering. All children received 1-week courses of prednisolone
(60 mg/m2/day) without tapering, and children with intermediate-risk and high-risk criteria received an additional
3-week course of dexamethasone (10 mg/m2/day) with tapering over a 9-day period
Cumulative dose of glucocorticoid therapy: all patients received 2100 mg/m2 + 157.5 mg/m2 prednisolone. In
addition, several courses (not defined) of 420 mg/m2/day prednisolone. Intermediate-risk and high-risk patients:
additional 210 mg/m2 + 26.25 mg/m2 dexamethasone
Duration of glucocorticoid therapy: induction therapy: 35 days of prednisolone + 9 days’ tapering doses. Additional
7-day courses of prednisolone. Intermediate-risk and high-risk patients: additional 21 days dexamethasone + 9 days
tapering doses
Methods of cessation of glucocorticoid therapy: 50% every 3 days over 9 days in total
No control intervention
Outcomes Specific HPA axis function test: low-dose ACTH stimulation test (1 µg tetracosactide (Synacthen, Novartis) between
8 and 10 a.m. (basal cortisol and after 30 minutes)
Moment of testing: for each child: before the 5-week course of prednisolone (weeks 1 to 5) and days 1, 3 and 5
after tapering was completed. Before the 1-week course of prednisolone (weeks 14 (standard risk), 28 (high risk) or
37 (intermediate risk)) and on day 2 after cessation. Before the 3-week course of dexamethasone (weeks 25 to 27
(intermediate risk) or 36 or 38 (high risk)), before tapering, and on days 1, 3 and 7 after tapering was completed.
The tests were performed during treatment for ALL
Cut-off limits defined by original studies: low-dose ACTH test: normal response > 500 nmol/L
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Notes Based on additional information provided by the authors, 5 patients were lost to follow-up
Length of follow-up after glucocorticoid therapy: varied
Risk factors were not evaluated
ACTH: adrenocorticotropic hormone
AIEOP: Associazione Italiana Ematologia e Oncologia
ALL: acute lymphoblastic leukaemia
CRH: corticotrophin-releasing hormone
HPA: hypothalamic-pituitary-adrenal
iv: intravenous
NOPHO: Nordic Society of Pediatric Hematology and Oncology
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bessho 1984 HPA axis was not examined
Birkebaek 1998 No data on intervention (doses, duration, methods of cessation of glucocorticoid therapy)
No data on cut-off limits of HPA axis function tests
No accurate data on follow-up period
Data on patients without cranial irradiation were not reported separately
Felder-Puig 2007 HPA axis function was only examined during glucocorticoid treatment
Lightner 1981 Patients received cranial irradiation
Pawlaczyk 1993 Patients received cranial irradiation
Silva 2006 Double publication of Cunha 2004
HPA: hypothalamic-pituitary-adrenal
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Risk of bias assessment criteria for observational studies
Internal validity External validity
Study group Selection bias (representative: yes/no):
• if it consisted of more than 90% of the original
cohort of ALL patients treated with glucocorticoids
• or if it was a random sample with respect to the
treatment
Reporting bias (well defined: yes/no):
• if the treatment protocol was mentioned
• and if the (cumulative) dose of glucocorticoid
treatment was mentioned
• and if the type of glucocorticoid treatment was
mentioned
• and if the duration of glucocorticoid treatment
was mentioned
• and if the method of cessation of glucocorticoid
treatment was mentioned
Follow-up Attrition bias (adequate: yes/no):
• if the outcome was assessed at the end date of the
study for 60% to 90% of the study group
• or if the outcome was assessed for more than 90%
of the study group but with an unknown end date
Reporting bias (well-defined: yes/no):
• if the length of follow-up was mentioned
• and if the frequency of measuring the outcomes
was mentioned
Outcome Detection bias (blinding: yes/no):
• if the outcome assessor was blinded to
glucocorticoid treatment
Reporting bias (well-defined: yes/no):
• if the methods of detection were described
• if the outcome definition was objective and
precise
Risk estimation Confounding (adjustment for other factors: yes/no):
• if important prognostic factors (i.e. age, sex, co-
treatment) or follow-up were taken adequately into
account
Analysis (well-defined: yes/no):
• if a relative risk, odds ratio, attributable risk,
linear or logistic regression model, mean difference, or
Chi2 statistic was calculated
Table 2. Risk of bias assessment criteria for randomised controlled trials
Selection bias
Sequence generation (adequate: yes/no):
• if the rule for allocating interventions to participants was based on some chance (random) process
Allocation concealment (adequate: yes/no):
• if the randomisation method did not allow investigator and participant to know or influence the allocation of treatment before
eligible participants entered the study
/ Performance bias
Blinding of care providers (yes/no):
• if knowledge of the allocated intervention was adequately prevented during the study
Blinding of participants (yes/no)
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Table 2. Risk of bias assessment criteria for randomised controlled trials (Continued)
• if knowledge of the allocated intervention was adequately prevented during the study
Detection bias
Blinding of outcome assessors (yes/no; assessed for each outcome separately):
• if knowledge of the allocated intervention was adequately prevented during the study
Attrition bias
Incomplete outcome data (adequate: yes/no; assessed for each outcome separately):
• if incomplete outcome (attrition and exclusions) data have been adequately addressed
Reporting bias
Selective outcome reporting (yes/no):
• if the reports of the study were free of suggestion of selective outcome reporting
Other bias
Other bias (yes/no):
• if the study was free of other problems (i.e. potential source of bias related to the specific study design, premature termination
of the study due to some data-dependent process, extreme baseline imbalance) that could put it at a high risk of bias
Table 3. Risk of bias in included observational studies
Study Represen-
tative study
group
Complete
follow-up
assessment
Blinded
outcome as-
sessor
Adjustment
important
con-
founders
Well-de-
fined study
group
Well-
defined fol-
low-up
Well-
defined
outcome
Well-
defined risk
estimation
Cunha 2004 No, based
on addi-
tional infor-
mation pro-
vided by the
authors, the
described
study group
did not con-
sist of more
than 90% of
the original
cohort and
was no ran-
dom sample
Yes, out-
come was as-
sessed for
60% to 90%
of the study
group at the
end date of
the study
Unclear if
outcome as-
sessor
was blinded
to the gluco-
corticoid
treatment
No, impor-
tant prog-
nostic fac-
tors or fol-
low-up were
not taken
into account
Yes, treat-
ment proto-
col and (cu-
mu-
lative) dose,
type, dura-
tion
and form of
cessation
of glucocor-
ticoid treat-
ment were
mentioned
Yes,
length of fol-
low-up and
frequency of
mea-
suring were
mentioned
Yes, meth-
ods of de-
tection were
described
and out-
come defini-
tion was ob-
jective and
precise
Yes,
mean differ-
ence was cal-
culated
Felner 2000 Yes, based
on addi-
tional infor-
mation pro-
vided by the
Yes, out-
come was as-
sessed for
60% to 90%
of the study
Unclear if
outcome as-
sessor
was blinded
to the gluco-
No, impor-
tant prog-
nostic fac-
tors or fol-
low-up were
No, treat-
ment proto-
col was not
mentioned
Yes,
length of fol-
low-up and
frequency of
mea-
Yes, meth-
ods of de-
tection were
described
and out-
Yes,
mean differ-
ence was cal-
culated
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Table 3. Risk of bias in included observational studies (Continued)
authors, the
described
study group
consisted of
more
than 90% of
the original
cohort
group at the
end date of
the study
corticoid
treatment
not taken
into account
suring were
mentioned
come defini-
tion was ob-
jective and
precise
Kuperman
2001
Yes, based
on addi-
tional infor-
mation pro-
vided by the
authors, the
described
study group
consisted of
more
than 90% of
the original
cohort
Yes, out-
come was as-
sessed for
60% to 90%
of the study
group at the
end date of
the study
Unclear if
outcome as-
sessor
was blinded
to the gluco-
corticoid
treatment
No, impor-
tant prog-
nostic fac-
tors or fol-
low-up were
not taken
into account
No, treat-
ment proto-
col was not
mentioned
Yes,
length of fol-
low-up and
frequency of
mea-
suring were
mentioned
Yes, meth-
ods of de-
tection were
described
and out-
come defini-
tion was ob-
jective and
precise
Yes,
mean differ-
ence was cal-
culated
Mahachok-
lertwattana
2004
Un-
clear if the
study group
consisted of
more
than 90% of
the original
cohort or if
it was a ran-
dom sample
Yes, out-
come was as-
sessed for
60% to 90%
of the study
group at the
end date of
the study
Unclear if
outcome as-
sessor
was blinded
to the gluco-
corticoid
treatment
No, impor-
tant prog-
nostic fac-
tors or fol-
low-up were
not taken
into account
Yes, treat-
ment proto-
col and (cu-
mu-
lative) dose,
type, dura-
tion
and form of
cessation
of glucocor-
ticoid treat-
ment were
mentioned
Yes,
length of fol-
low-up and
frequency of
mea-
suring were
mentioned
Yes, meth-
ods of de-
tection were
described
and out-
come defini-
tion was ob-
jective and
precise
Yes,
mean differ-
ence was cal-
culated
Petersen
2003
Yes, the de-
scribed
study group
consisted of
more
than 90% of
the original
cohort
Yes, out-
come was as-
sessed for
60% to 90%
of the study
group at the
end date of
the study
Unclear if
outcome as-
sessor
was blinded
to the gluco-
corticoid
treatment
Yes, impor-
tant prog-
nostic fac-
tors or fol-
low-up were
taken into
account
Yes, treat-
ment proto-
col and (cu-
mu-
lative) dose,
type and du-
ration
of glucocor-
ticoid treat-
ment were
mentioned.
Information
Yes,
length of fol-
low-up and
frequency of
mea-
suring were
mentioned
Yes, meth-
ods of de-
tection were
described
and out-
come defini-
tion was ob-
jective and
precise
No, relative
risk, odds ra-
tio,
attributable
risk,
linear or lo-
gistic regres-
sion model,
mean differ-
ence, or Chi
2 statistic
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Table 3. Risk of bias in included observational studies (Continued)
on the form
of cessation
of glucocor-
ticoid treat-
ment was
based on ad-
di-
tional infor-
mation pro-
vided by the
authors
were not cal-
culated
Rix 2005 Yes, the de-
scribed
study group
consisted of
more
than 90% of
the original
cohort
Yes, out-
come was as-
sessed for
60% to 90%
of the study
group at the
end date of
the study
No,
the outcome
assessor was
not blinded
to the gluco-
corticoid
treatment
Yes, impor-
tant prog-
nostic fac-
tors or fol-
low-up were
taken into
account
Yes, treat-
ment proto-
col and (cu-
mu-
lative) dose,
type and du-
ration
of glucocor-
ticoid treat-
ment were
mentioned.
Information
on the form
of cessation
of glucocor-
ticoid treat-
ment was
based on ad-
di-
tional infor-
mation pro-
vided by the
authors
Yes,
length of fol-
low-up and
frequency of
mea-
suring were
mentioned
Yes, meth-
ods of de-
tection were
described
and out-
come defini-
tion was ob-
jective and
precise
Yes,
mean differ-
ence was cal-
culated
Table 4. Risk of bias in included randomised controlled trial
Study Ad-
equate sequence
generation?
Ade-
quate allocation
concealment?
Blinding? Incomplete out-
come data ad-
dressed?
Free of selective
reporting?
Free of other
bias?
Einaudi 2008 Yes, according to
additional infor-
mation provided
by the authors,
the rule for allo-
cating interven-
Yes, according to
additional infor-
mation provided
by the authors,
the randomisa-
tion method did
Based on ad-
ditional informa-
tion provided by
the authors, care
providers,
patients and out-
Yes, there are no
missing outcome
data
No, “adrenal
func-
tion completely
recovered in the
12 children eval-
uated with sub-
Yes
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Table 4. Risk of bias in included randomised controlled trial (Continued)
tions to partici-
pants was based
on some chance
(random) process
not allow investi-
gator and partic-
ipant to know or
influence the al-
location of treat-
ment before eli-
gible participants
entered the study
come assessors
were not blinded
sequent low-dose
ACTH test (in
4, 3, and 5 pa-
tients after 4, 8
and 10 weeks, re-
spectively)
”. However, it
was not reported
which of these
patients received
prednisone and
which of them
received dexam-
ethasone. There-
fore, not all of the
study’s pre-speci-
fied primary out-
comes were re-
ported
Table 5. Prevalence and duration of adrenal insufficiency evaluated by an ACTH stimulation test
Felner et al. Therapy: dexamethasone (cumulative dose 168 mg/m2)
Time after cessation Before 1 day 4 weeks 8 weeks
n insufficient/n total 0/10 10/10 3/10 0/10
Petersen et al. (1) Therapy: prednisolone (cumulative dose 2257.5 mg/m2)a
Time after cessation 1 week 3 weeks 7 weeks End of follow-up: 10, 11, 11 and 19 weeks, respectively
n insufficient/n total 7/10 6/10 4/10 4/10
Petersen et al. (2) Therapy: dexamethasone (cumulative dose 236.25 mg/m2)b
Time after cessation 1 week 3 weeks 7 weeks End of follow-up: 16, 33 and 34 weeks, respectively
n insufficient/n total 5/7 4/7 3/7 2/7
a One patient received additional 840 mg/m2 prednisolone during the period of adrenal insufficiency.
b These patients received prednisolone 2257.5 mg/m2 as induction therapy before. Three high-risk patients received additional 560
mg/m2 prednisolone in advance. One patient received additional 420 mg/m2 prednisolone during the period of adrenal insufficiency
and two patients received additional 1260 mg/m2 prednisolone during the period of adrenal insufficiency.
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Table 6. Prevalence and duration of adrenal insufficiency evaluated by a low-dose ACTH stimulation test
Mahachoklertwat-
tana et al.
Therapy: prednisolone (cumulative dose 1120 mg/m2)a
Time after cessation 2 weeks 4 weeks 8 weeks 12 weeks 20 weeks
n insufficient/n to-
tal
11/24 9/24 7/24 3/24 3/24
Rix et al. (1) Therapy: prednisolone (cumulative dose 2257.5 mg/m2)
Time after cessation Before 1 day 3 days 5 days
n insufficient/n to-
tal
0/13 16/17 8/15 8/17
Rix et al. (2) Therapy: prednisolone (cumulative dose 420 mg/m2)b
Time after cessation Before 2 days
n insufficient/n to-
tal
2/13 13/13
Rix et al. (3) Therapy: dexamethasone (cumulative dose 236.25 mg/m2)b
Time after cessation Before 1 day 3 days 7 days
n insufficient/n to-
tal
0/5 2/2 3/5 1/5
Einaudi et al. (1) Therapy: prednisolone (cumulative dose 1477.5 mg/m2)c
Time after cessation 1 day 7 to 14 days 28 days 42 days 10 weeks
n insufficient/n to-
tal
32/40 8/32 5/8 5/5 0/5
Einaudi et al. (2) Therapy: dexamethasone (cumulative dose 246.25 mg/m2)c
Time after cessation 1 day 7 to 14 days 28 days 42 days 10 weeks
n insufficient/n to-
tal
20/24 4/20 3/4 3/3 0/3
a Four weeks after completion of the induction therapy, the patients received maintenance therapy consisting of a 7-day course of high-
dose dexamethasone 8 mg/m2/day, every 4 weeks. The cumulative dose depended on how long the patient had been followed up.
b All patients first received prednisolone (cumulative dose 2257.5 mg/m2).
c After 7 days of prednisone (60 mg/m2/day, cumulative dose: 420 mg/m2).
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Table 7. Prevalence and duration of adrenal insufficiency evaluated by basal morning cortisol values
Cunha et al. No data on patient level were available
Time after cessation
n insufficient/n total
Kuperman et al. Therapy: dexamethasone (cumulative dose 252 mg/m2)a
Time after cessation Before 1 week 2 weeks
n insufficient/n total 0/15 4/15 4/14
a Results based on basal cortisol levels; cut-off level 7 µg/dL = 194 nmol/L.
A P P E N D I C E S
Appendix 1. Search strategy for PubMed
1. For children the following MeSH headings and text words were used:
infant OR infan* OR newborn OR newborn* OR new-born* OR baby OR baby* OR babies OR neonat* OR perinat* OR postnat*
OR child OR child* OR schoolchild* OR schoolchild OR school child OR school child* OR kid OR kids OR toddler* OR adolescent
OR adoles* OR teen* OR boy* OR girl* ORminors ORminors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar*
OR puberty OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR pediatric* OR paediatric* OR peadiatric*
OR schools OR nursery school* OR preschool* OR pre school* OR primary school* OR secondary school* OR elementary school*
OR elementary school OR high school* OR highschool* OR school age OR schoolage OR school age* OR schoolage* OR infancy
OR schools, nursery OR infant, newborn
2. For acute lymphocytic leukemia the following MeSH headings and text words were used:
acute lymphocytic leukemia OR childhood ALL OR Precursor Cell Lymphoblastic Leukemia-Lymphoma OR Precursor Cell Lym-
phoblastic Leukemia Lymphoma OR Leukemia, Lymphoblastic OR Leukemia, Lymphoblastic, Acute OR Leukemia, Lymphocytic,
Acute OR Leukemia, Lymphoid, Acute OR Lymphoblastic Leukemia, Acute OR Acute Lymphoblastic Leukemia OR Leukemia, Acute
Lymphoblastic OR Lymphoblastic Lymphoma OR Lymphomas, Lymphoblastic OR Lymphocytic Leukemia, Acute OR Acute Lym-
phocytic Leukemia OR Leukemia, Acute Lymphocytic OR Lymphoma, Lymphoblastic OR Acute Lymphoid Leukemia OR Leukemia,
Acute Lymphoid OR Lymphoid Leukemia, Acute OR Lymphoblastic Leukemia OR Leukemia, Lymphocytic, Acute, L1 OR Lympho-
cytic Leukemia, L1 OR L1 Lymphocytic Leukemia OR Leukemia, L1 Lymphocytic OR Lymphoblastic Leukemia, Acute, Childhood
OR Lymphoblastic Leukemia, Acute, L1 OR ALL, Childhood OR Childhood ALL OR Leukemia, Lymphoblastic, Acute, L1 OR
Leukemia, Lymphocytic, Acute, L2 OR Lymphocytic Leukemia, L2 OR L2 Lymphocytic Leukemia OR Leukemia, L2 Lymphocytic
OR Lymphoblastic Leukemia, Acute, Adult OR Lymphoblastic Leukemia, Acute, L2 OR Leukemia, Lymphoblastic, Acute, L2 OR
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive OR ((akut* OR acut*) AND ((leukemi* OR leukaemi*) OR (lymphocyt* OR
lymphoblast*)))
3. For glucocorticoids the following MeSH headings and text words were used:
SteroidOR steroids OR steroid*OR glucocorticoid OR glucocorticoids OR glucocorticoid* OR corticoid OR corticoids OR corticoid*
OR adrenal cortex hormones OR hormones, adrenal cortex OR
prednison OR prednisone OR 53-03-2 OR Dehydrocortisone OR delta-Cortisone OR Winpred OR ICN Brand of Prednisone OR
Cortancyl OR Panafcort OR Aventis Brand of Prednisone OR Cutason ORmibe Brand of Prednisone ORDacortin ORMerck Brand
of Prednisone ORDecortin Brand of Prednisone ORDecortisyl ORHoechst Brand of Prednisone ORDeltasone OR Pharmacia Brand
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of Prednisone OR Encortone OR Encorton OR Enkortolon OR Kortancyl OR Liquid Pred OR Meticorten OR Schering-Plough
Brand of Prednisone OR Orasone OR Solvay Brand of Prednisone OR Panasol OR Seatrace Brand of Prednisone OR Predni Tablinen
OR Lichtenstein Brand of Prednisone OR Prednidib OR Diba Brand of Prednisone OR Predniment OR Ferring Brand of Prednisone
OR Prednison acsis OR acis Brand of Prednisone OR Prednison Galen OR GALENpharma Brand of Prednisone OR Prednison
Hexal OR Hexal Brand of Prednisone OR Pronisone OR Rectodelt OR Trommsdorff Brand of Prednisone OR Ultracorten OR Sone
OR Fawns & McAllan Brand of Prednisone OR Sterapred OR Merz Brand of Prednisone OR Apo-Prednisone OR Apotex Brand of
Prednisone OR Cortan ORHalsey Drug Brand of Prednisone OR prednisolon OR 50-24-8 OR dexamethason OR dexametasone OR
dexamethasone OR 50-02-2 OR Methylfluorprednisolone OR Hexadecadrol OR Maxidex OR Alcon Brand of Dexamethasone OR
Dexamethasone Intensol OR Roxane Brand of Dexamethasone OR Decaject ORMerz Brand 1 of Dexamethasone OR Oradexon OR
Decameth OR Foy Brand of Dexamethasone OR Decaspray OR Merck Brand of Dexamethasone OR Dexasone OR ICN Brand of
Dexamethasone OR Hexadrol OR Millicorten OR Dexpak OR ECR Brand of Dexamethasone OR Decaject-L.A. OR Decaject L.A.
OR Merz Brand 2 of Dexamethasone
4. For HPA function the following MeSH headings and text words were used:
HPA ORHPA axis OR hypothalamic-pituitary-adrenal OR hypothalamic-pituitary-adrenal axis OR adrenal insufficiency OR adrenal
axis OR Hypothalamo-Hypophyseal System OR hypothalamic insufficiency OR pituitary OR Pituitary-Adrenal Function Tests OR
Function Test, Pituitary-Adrenal OR Function Tests, Pituitary-Adrenal OR Pituitary Adrenal Function Tests OR Pituitary-Adrenal
Function Test OR Test, Pituitary-Adrenal Function OR Tests, Pituitary-Adrenal Function OR Pituitary-Adrenal System OR Pituitary
Adrenal System OR Pituitary-Adrenal Systems OR System, Pituitary-Adrenal OR Systems, Pituitary-Adrenal OR
hypothalamus OR hypothalam* OR hypophysis OR hypophys* OR Hypothalamo-Hypophyseal OR Pituitary Gland OR Pituitary
Glands ORHypothalamic Hormones ORHormones, Hypothalamic ORHypothalamic Pituitary-Regulating Peptides ORHypothala-
mic Pituitary Regulating Peptides OR Peptides, Hypothalamic Pituitary-Regulating OR Pituitary-Regulating Peptides, Hypothalamic
OR Hypothalamic Pituitary-Regulating Hormones OR Hormones, Hypothalamic Pituitary-Regulating OR Hypothalamic Pituitary
Regulating Hormones OR Pituitary-Regulating Hormones, Hypothalamic OR Pituitary Hormones OR Hormones, Pituitary OR
adrenal glands OR
adrenal function test[all fields] OR adrenal function tests[all fields] OR adrenal function testing [all fields] OR adrenal function
evaluation[all fields] OR ACTH stimulation test[all fields] OR ACTH stimulation tests[all fields] OR ACTH stimulation testing [all
fields] OR ACTH test[all fields] OR ACTH tests[all fields] OR ACTH testing [all fields] OR ACTH evaluation[all fields] OR CRH
stimulation test[all fields] OR CRH stimulation tests[all fields] OR CRH stimulation testing [all fields] OR CRH test[all fields] OR
CRH tests[all fields] OR CRH testing [all fields] OR CRH evaluation[all fields] OR glucagon stimulation test[all fields] OR glucagon
stimulation tests[all fields] OR glucagon stimulation testing [all fields] OR glucagon test [all fields] OR glucagon tests[all fields] OR
glucagon testing [all fields] OR glucagon evaluation[all fields] OR fasting cortisol OR morning cortisol
Final search: 1 AND 2 AND 3 AND 4
[* = 1 or more characters]
Appendix 2. Search strategy for EMBASE (Ovid)
1. For children the following Emtree terms and text words were used:
1. infant/ or infancy/ or newborn/ or baby/ or child/ or preschool child/ or school child/
2. adolescent/ or juvenile/ or boy/ or girl/ or puberty/ or prepuberty/ or pediatrics/
3. primary school/ or high school/ or kindergarten/ or nursery school/ or school/
4. or/1-3
5. (infant$ or newborn$ or (new adj born$) or baby or baby$ or babies or neonate$ or perinat$ or postnat$).mp.
6. (child$ or (school adj child$) or schoolchild$ or (school adj age$) or schoolage$ or (pre adj school$) or preschool$).mp.
7. (kid or kids or toddler$ or adoles$ or teen$ or boy$ or girl$).mp.
8. (minors$ or (under adj ag$) or underage$ or juvenil$ or youth$).mp.
9. (puber$ or pubescen$ or prepubescen$ or prepubert$).mp.
10. (pediatric$ or paediatric$ or peadiatric$).mp.
11. (school or schools or (high adj school$) or highschool$ or (primary adj school$) or (nursery adj school$) or (elementary adj school)
or (secondary adj school$) or kindergar$).mp.
12. or/5-11
13. 4 or 12
2. For acute lymphocytic leukemia the following Emtree terms and text words were used:
1. acute lymphocytic leukemia.mp. or exp Acute Lymphocytic Leukemia/
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2. (childhood adj ALL).
3. precursor cell lymphoblastic leukemia-lymphoma.mp. or exp Acute Lymphoblastic Leukemia/
4. lymphoblastic lymphoma.mp. or exp Lymphoblastoma/
5. (acute lymphoblastic leukemia or acute lymphoid leukemia).mp.
6. lymphoblastic leukemia.mp. or exp Lymphatic Leukemia/
7. (L1 lymphocytic leukemia or L2 lymphocytic leukemia).mp.
8. (lymphoblastic lymphoma or lymphoblastic lymphomas).mp. or exp lymphatic leukemia/
9. childhood acute lymphoblastic leukemia.mp. or exp Childhood Leukemia/
10. philadelphia positive acute lymphoblastic leukemia.mp.
11. ((akut$ or acut$) and (leukemi$ or leukaemi$ or lymphocyt$ or lymphoblast$)).mp.
12. or/1-11
3. For glucocorticoids the following Emtree terms and text words were used:
1. steroid.mp. or exp steroid/
2. (steroids or steroid$).mp.
3. glucocorticoid.mp. or exp glucocorticoid/
4. (glucocorticoids or glucocorticoid$).mp.
5. corticoid.mp. or exp corticosteroid/
6. (corticoids or corticoid$).mp.
7. adrenal cortex hormones.mp.
8. prednison.mp. or exp prednisone/
9. prednisone.mp.
10. 53-03-2.rn.
11. (dehydrocortisone or delta-cortisone or winpred or cortancyl or panafcort or cutason or dacortin or decortisyl).mp.
12. (deltasone or encortone or encorton or emkortolon or kortancyl or meticorten).mp.
13. (orasone or panasol or predni tablinen or prednidib or predniment or prednison acsis).mp.
14. (prednison galen or prednison hexal or pronisone or rectodelt or ultracorten or sone).mp.
15. (sterapred or apo-prednisone or cortan or prednisolon).mp.
16. 50-24-8.rn.
17. exp dexamethasone/
18. (dexamethason or dexamethasone or dexametasone).mp.
19. 50-02-2.rn.
20. (methylfluorprednisolone or hexadecadrol or maxidex or dexamethasone intensol).mp.
21. (decaject or oradexon or decameth or decaspray or dexasone or hexadrol or millicorten or dexpak or decaject-la or decaject la).mp.
22. or/1-21
4. For HPA function the following Emtree terms and text words were used:
1. exp hypothalamus hypophysis adrenal system/
2. (HPA or HPA axis).mp.
3. (hypothalamic-pituitary-adrenal or hypothalamic-pituitary-adrenal axis).mp.
4. adrenal insufficiency.mp. or exp adrenal insufficiency/
5. adrenal axis.mp.
6. hypothalamo-hypophyseal system.mp. or exp hypothalamus hypophysis system/
7. hypothalamic insufficiency.mp.
8. pituitary.mp.
9. (pituitary-adrenal function tests or pituitary-adrenal function test).mp.
10. (pituitary adrenal function tests or pituitary adrenal function test).mp.
11. (pituitary adrenal system or pituitary-adrenal system or pituitary adrenal systems or pituitary-adrenal systems).mp.
12. exp hypothalamus/ or hypothalamus.mp.
13. hypothalam$.mp.
14. exp hypophysis/ or hypophysis.mp.
15. hypophys$.mp.
16. exp hypothalamus hypophysis system/ or hypothalamo-hypophyseal.mp.
17. (pituitary gland or pituitary glands).mp.
18. hypothalamic hormones.mp. or exp hypothalamus hormone/
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19. (hypothalamic pituitary-regulating peptides or hypothalamic pituitary regulating peptides).mp.
20. (hypothalamic pituitary-regulating hormones or hypothalamic pituitary regulating hormones).mp.
21. pituitary hormones.mp. or exp hypophysis hormone/
22. adrenal glands.mp. or exp adrenal gland/
23. adrenal function test.mp. or exp endocrine function test/
24. (adrenal function test or adrenal function testing or adrenal function evaluation).mp.
25. ACTH stimulation test.mp. or exp corticotropin test/
26. (ACTH stimulation tests or ACTH stimulation testing).mp.
27. (ACTH test or ACTH tests or ACTH testing or ACTH evaluation).mp.
28. (CRH stimulation test or CRH stimulation tests or CRH stimulation testing).mp.
29. (CRH test or CRH tests or CRH testing or CRH evaluation).mp.
30. (glucagon stimulation test or glucagon stimulation tests or glucagon stimulation testing).mp.
31. (glucagon test or glucagon tests or glucagon testing or glucagon evaluation).mp.
32. (fasting cortisol or morning cortisol).mp.
33. or/1-32
Final search: 1 AND 2 AND 3 AND 4
[mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name; $
= 1 or more characters; / = Emtree term; rn = registry number]
Appendix 3. Search strategy for the Cochrane Central Register of Controlled Trials (CENTRAL)
1. For children the following text words were used:
(infant OR infan* OR newborn OR newborn* OR new-born* OR baby OR baby* OR babies OR neonat* OR child OR child* OR
schoolchild* OR schoolchild OR school child OR school child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR teen*
OR boy* OR girl* OR minors OR minors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar* OR puberty OR
puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR pediatric* OR paediatric* OR peadiatric* OR schools OR
nursery school* OR preschool* OR pre school* OR primary school* OR secondary school* OR elementary school* OR elementary
school OR high school* OR highschool* OR school age OR schoolage OR school age* OR schoolage* OR infancy)
2. For acute lymphocytic leukemia the following text words were used:
acute lymphocytic leukemia OR childhood ALL OR Precursor Cell Lymphoblastic Leukemia-Lymphoma OR Precursor Cell Lym-
phoblastic Leukemia LymphomaORAcute Lymphoblastic LeukemiaORLymphoblastic LymphomaORAcute Lymphocytic Leukemia
OR Acute Lymphoid Leukemia OR Lymphoblastic Leukemia OR L1 Lymphocytic Leukemia OR L2 Lymphocytic Leukemia OR
((akut* OR acut*) AND (leukemi* OR leukaemi*) OR (lymphocyt* OR lymphoblast*))
3. For glucocorticoids the following text words were used:
SteroidOR steroidsOR steroid*ORglucocorticoidOR glucocorticoidsOR glucocorticoid*OR corticoidOR corticoidsOR corticoid*
OR adrenal cortex hormones OR prednison OR prednisone ORDehydrocortisone OR delta-Cortisone ORWinpred OR ICN Brand
of Prednisone ORCortancyl OR Panafcort OR Aventis Brand of Prednisone ORCutason ORmibe Brand of Prednisone ORDacortin
OR Merck Brand of Prednisone OR Decortin Brand of Prednisone OR Decortisyl OR Hoechst Brand of Prednisone OR Deltasone
OR Pharmacia Brand of Prednisone OR Encortone OR Encorton OR Enkortolon OR Kortancyl OR Liquid Pred ORMeticorten OR
Schering-Plough Brand of Prednisone OROrasone OR Solvay Brand of Prednisone OR Panasol OR Seatrace Brand of Prednisone OR
Predni Tablinen ORLichtenstein Brand of Prednisone ORPrednidib ORDiba Brand of Prednisone ORPredniment ORFerring Brand
of Prednisone OR Prednison acsis OR acis Brand of Prednisone OR Prednison Galen OR GALENpharma Brand of Prednisone OR
Prednison Hexal OR Hexal Brand of Prednisone OR Pronisone OR Rectodelt OR Trommsdorff Brand of Prednisone OR Ultracorten
OR Sone OR Fawns & McAllan Brand of Prednisone OR Sterapred OR Merz Brand of Prednisone OR Apo-Prednisone OR Apotex
Brand of Prednisone OR Cortan OR Halsey Drug Brand of Prednisone OR prednisolon OR dexamethason OR dexametasone OR
dexamethasone ORMethylfluorprednisolone ORHexadecadrol ORMaxidex ORAlcon Brand of Dexamethasone ORDexamethasone
Intensol OR Roxane Brand of Dexamethasone OR Decaject OR Merz Brand 1 of Dexamethasone OR Oradexon OR Decameth OR
Foy Brand of Dexamethasone OR Decaspray OR Merck Brand of Dexamethasone OR Dexasone OR ICN Brand of Dexamethasone
OR Hexadrol OR Millicorten OR Dexpak OR ECR Brand of Dexamethasone OR Decaject-L.A. OR Decaject L.A. OR Merz Brand
2 of Dexamethasone
4. For HPA function the following text words were used:
HPA ORHPA axis OR hypothalamic-pituitary-adrenal OR hypothalamic-pituitary-adrenal axis OR adrenal insufficiency OR adrenal
axis OR Hypothalamo-Hypophyseal System OR hypothalamic insufficiency OR pituitary OR Pituitary-Adrenal Function Tests OR
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Pituitary Adrenal Function Tests OR Pituitary-Adrenal Function Test OR Pituitary-Adrenal System OR Pituitary Adrenal System OR
Pituitary-Adrenal Systems OR hypothalamus OR hypothalam* OR hypophysis OR hypophys* OR Hypothalamo-Hypophyseal OR
PituitaryGlandORPituitaryGlandsORHypothalamicHormonesORHypothalamic Pituitary-RegulatingPeptidesORHypothalamic
Pituitary Regulating Peptides OR Hypothalamic Pituitary-Regulating Hormones OR Hypothalamic Pituitary Regulating Hormones
OR Pituitary Hormones OR adrenal glands OR adrenal function test OR adrenal function tests OR adrenal function testing OR
adrenal function evaluation OR ACTH stimulation test OR ACTH stimulation tests OR ACTH stimulation testing OR ACTH
test OR ACTH tests OR ACTH testing OR ACTH evaluation OR CRH stimulation test OR CRH stimulation tests OR CRH
stimulation testing OR CRH test OR CRH tests OR CRH testing OR CRH evaluation OR glucagon stimulation test OR glucagon
stimulation tests OR glucagon stimulation testing OR glucagon test OR glucagon tests OR glucagon testing OR glucagon evaluation
OR fasting cortisol OR morning cortisol
Final search: 1 and 2 and 3 and 4
The search was performed in title, abstract or keywords.
Appendix 4. Search strategy for conference proceedings
Search used in the International Society of Paediatric Oncology (SIOP) proceedings:
(http://www.siop.nl)
Separate searches were done for the following search terms:
HPA
HPA axis
adrenal
hypothalamus
hypothalamic-pituitary-adrenal
Search used in American Society of Clinical Oncology (ASCO) proceedings:
(http://www.asco.org)
Only annual meetings were searched (since molecular markers, breast, genitourinary, gastrointestinal and prostate specific meetings
were not expected to yield results that involved HPA axis suppression during acute lymphoblastic leukemia).
Separate searches were done for the following search terms:
HPA
HPA axis
adrenal
hypothalamus
hypothalamic-pituitary-adrenal
The search was performed in title field.
Appendix 5. Search strategy for ongoing trials registers
Search used in the International Standard Randomized Controlled Trial Number (ISRCTN) register and the National Institutes
of Health (NIH) register for ongoing trials:
(http://www.controlled-trials.com)
Separate searches were done for the following search terms:
HPA
HPA axis
adrenal
hypothalamus
hypothalamic-pituitary-adrenal
The search was performed in title field.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In addition to the primary objective stated in the protocol to examine the occurrence of HPA axis suppression after treatment with
glucocorticoids for childhood ALL, we have also studied the duration of HPA axis suppression.
The data extraction and the ’Risk of bias’ assessment of the included studies were performed by one review author andwere independently
checked by two other review authors (as opposed to the protocol, where it was stated that two independent review authors would do
this).
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Insufficiency [∗chemically induced]; Antineoplastic Agents, Hormonal [administration & dosage; adverse effects]; Cohort
Studies; Dexamethasone [administration & dosage; adverse effects]; Glucocorticoids [administration & dosage; ∗adverse effects];
Hypothalamo-Hypophyseal System [∗drug effects]; Pituitary-Adrenal System [∗drug effects]; Precursor Cell Lymphoblastic Leukemia-
Lymphoma [∗drug therapy]; Prednisolone [administration & dosage; adverse effects]; Randomized Controlled Trials as Topic
MeSH check words
Child; Humans
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